About
New Antitumor Drug Project ( HJ550 ):
the first bivalent platinum drug targeting the tumor microenvironment, redefine the first-line treatment paradigm for cancer.
Technology
Bio-TechHealth Technology
Additional Information
Other Place of Business
North AmericaHong KongMainland China
Terms and Conditions & Disclaimer
I agreeRepresentatives
CEO
Shanghai Haiju Biotechnology Co., Ltd.
Marketplace (2)
Project
Novel Platinum-Based Drug (HJ-550 )
HJ-550 may redefine the sequence of first-line cancer therapies and mark a milestone in the history of oncology treatment.
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Convertible Loan
- Equity (private)
- Financial Services
- Investment Banking
- Professional Services
- Mergers & Acquisition
- 500,001 to 1,000,000 USD
- Direct Equity Investment
- Institutional Investment
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
AuthorCEO at Shanghai Haiju Biotechnology Co., Ltd.
China
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
protein kinase inhibitors with ingenious molecular designs
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Financial Services
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Investment / Financing Discussion
- M&A / Strategic Acquisition Opportunity
AuthorCEO at Shanghai Haiju Biotechnology Co., Ltd.
China